Farber's disease without central nervous system involvement: bone-marrow transplantation provides a promising new approach
Authors:
- 1 December 2006
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (12) , 1665-1666
Abstract
Farber’s disease is a lysosomal storage disorder caused by acid ceramidase deficiency.1 The main symptoms in patients without central nervous system (CNS) involvement (type 2/3), are caused by leucocyte dysregulation,2 with impaired apoptosis and signal transduction caused by intracellularly accumulated ceramide, leading to the inflammatory component of this disorder, with swelling of joints, granuloma formation, contractures and inflammatory airway involvement.6 Current treatment focuses on pain management, physical treatment, surgical correction of contractures and treatment with anti-inflammatory drugs. In rheumatoid disorders such as juvenile rheumatoid arthritis, immunosuppression or autologous haematopoietic stem cell transplantation (HSCT) can afford a substantial benefit, as treatment is based on suppression of abundant inflammatory responses by …Keywords
This publication has 5 references indexed in Scilit:
- Successful hematopoietic stem cell transplantation in farber diseaseThe Journal of Pediatrics, 2004
- The role of ceramide in receptor- and stress-induced apoptosis studied in acidic ceramidase-deficient Farber disease cellsOncogene, 2001
- Bone marrow transplantation for infantile ceramidase deficiency (Farber disease)Bone Marrow Transplantation, 2000
- Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndromeBlood, 1996
- A case of lipogranulomatosis Farber: some clinical and ultrastructural aspectsEuropean Journal of Pediatrics, 1985